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Phosphatase andTENsin homolog deleted on chromosome 10 (PTEN) is a tumor suppres-
sor gene located at chromosome 10q23.31, encoding for a 403-amino acid protein that
possesses both lipid and protein phosphatase activities. The main function of PTEN is to
block the PI3K pathway by dephosphorylating phosphatidylinositol (PI) 3,4,5-triphosphate
to PI-4,5-bisphosphate thus counteracting PI3K function. PTEN inactivation is a frequent
event in many cancer types and can occur through various genetic alterations including
point mutations, large chromosomal deletions, and epigenetic mechanisms. In colorec-
tal cancer (CRC) PTEN is altered through mixed genetic/epigenetic mechanisms (typically:
mutations and promoter hypermethylation or 10q23 LOH and promoter hypermethylation),
which lead to the biallelic inactivation of the protein in 20–30% of cases. The role of PTEN
as a prognostic and predictive factor in CRC has been addressed by relatively few works.
This review is focused on the report and on the discussion of the studies investigating
these aspects. Overall, at the moment, there are conflicting results and, therefore it has
not been clarified whether PTEN might play a prognostic role in CRC. The same is valid
also for the predictive role, leading to the fact that PTEN evaluation cannot be used in
routinely diagnosis for the early identification of patients who might be addressed to the
treatment with EGFR-targeted therapies, at odds with other genetic alterations belonging
to EGFR-downstream pathways. The reason of discordant results may be attributable to
several issues: (1) the size of the analyzed cohort, (2) patients inclusion criteria, (3) the
methods of assessing PTEN alteration. In particular, there are no standardized methods to
evaluate this marker, especially for immunohistochemistry, a technique suffering of intra
and inter-observer variability due to the semi-quantitative character of such an analysis.
In conclusion, much work, especially in large and homogeneous cohorts of cases from
different laboratories, has to be done before the establishment of PTEN as prognostic or
predictive marker in CRC.
Keywords: PTEN, colorectal cancer, mutation, immunohistochemistry, prognosis, predictive, EGFR-targeted
therapies
INTRODUCTION
Phosphatase and TENsin homolog deleted on chromosome 10
(PTEN ), known also as mutated in multiple advanced cancer 1
(MMAC1), is a tumor suppressor gene located at chromosome
10q23.31 and encodes for a 403-amino acid protein that possesses
both lipid and protein phosphatase activities. The crystal struc-
ture of PTEN revealed two major functional domains (a phos-
phatase domain and a C2 domain) and three structural regions
[a short N-terminal phosphatidylinositol (PI)-4,5-bisphosphate
(PIP2) binding domain and a C-terminal tail containing PEST
sequences and a PDZ-interaction motif] (Figure 1) (1). The
PTEN protein is principally involved in the homeostatic main-
tenance of PI3K/Akt signaling originating from EGFR activation
(or activation of other tyrosine kinase receptors or G-protein-
coupled receptors) (Figure 2). Its typical function consists of
the dephosphorylation of the lipid-signaling second messenger
PI 3,4,5-triphosphate (PIP3), a lipid product of the PI-3-kinase
(PI3K) (2), thereby directly antagonizing the PI3K function and
blocking therefore the activation of downstream signaling events,
including PDK1 (akt) and akt/mammalian target of rapamycin
(mTOR). The opposite biochemical reaction is catalyzed by PI3Ks,
which are associated with cell growth and cell survival (Figure 2).
Thus PTEN, which counteracts PI3Ks activity, is involved in inhi-
bition of cell cycle progression, induction of cell death, modulation
of arrest signal, and stimulation of angiogenesis (3).
The lipid phosphatase activity of PTEN is the best-
characterized physiological function contributing to the tumor
suppressor function of PTEN. As no other redundant and/or com-
pensatory family members have been found, PTEN is the only
known lipid phosphatase counteracting the PI3K pathway. It is
not surprising that loss of PTEN function, resulting therefore in
increased PIP3 and persistent activation of PI3K effectors, has an
important impact on multiple aspects of cancer development such
as cell proliferation, apoptosis resistance, angiogenesis, metabo-
lism regulation, genomic instability, stem cell self-renewal, cellular
senescence, and cell migration and metastasis (4, 5).
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FIGURE 1 | PTEN protein structure. PTEN is composed of 403-amino
acids and contains: a N-terminal region of 185 aminoacids (1–185)
composed by a PIP2-binding domain (PBD) and by a phosphatase domain
of 218 aminoacid (186–403), and a C-terminal region composed by a C2
domain and by a C-terminal tail containing two PEST (proline, glutamic acid,
serine, threonine) sequences, and a PDZ-interaction motif at the end.
FIGURE 2 |The PI3K-PTEN-Akt pathway. The main function of PTEN
consists in the regulation of the PI3K/Akt/mTOR. In response to
extracellular stimuli (e.g., presence of insulin, growth factors, chemokines),
PI3K is activated by tyrosine kinase receptors or G-protein-coupled
receptors and it phosphorylates PIP2 to generate PIP3 which in turn
phosphorylates and activates Akt. PTEN is a lipid phosphatase that
antagonizes the action of PI3K by dephosphorylating PIP3 to generate PIP2
(thus blocking the PI3K signaling cascade).
In its inactive state, PTEN is phosphorylated on a cluster of ser-
ine and threonine residues located on its C-terminal tail, leading
to a closed PTEN state and maintaining PTEN protein in a stable
conformation. When PTEN is being activated, dephosphoryla-
tion of its C-terminal tail opens its phosphatase domain, thereby
increasing PTEN activity. Meanwhile, the open state of PTEN is
more susceptible to ubiquitin-mediated proteasomal degradation
(4, 6): therefore, this mechanism is a negative feed-back leading
to decreasing and switching off the effect of PTEN, in absence of
specific stimuli.
The functionality of PTEN is also regulated by subcellular
localization. PTEN is well characterized as a cytosolic protein
that is recruited to the membrane by interacting with a num-
ber of membrane-anchored proteins, via its C-terminal PDZ
domain and PIP2-binding domain (7). In addition, PTEN mono-
ubiquitination controls PTEN nuclear entry. In some tumors,
the subcellular localization of PTEN protein seems to mediate
its activity (8). The absence of PTEN has been reported to be
associated with more aggressive diseases and with high degree
of neoplastic transformation, suggesting an important nuclear
function for PTEN in tumor suppression (9, 10).
A number of factors have been shown to transcriptionally
regulate PTEN mRNA [reviewed by Song et al. (5)], includ-
ing peroxisome proliferation-activated receptor γ (PPARγ), early
growth-response protein 1 (EGR1), and p53. PTEN mRNA is
also post-transcriptionally regulated by PTEN -targeting microR-
NAs such as miR19 and miR21 and is now emerging that also
PTEN pseudogene (PTENP1) may be able to regulate PTEN
expression (5).
PTEN loss of function occurs in a wide spectrum of human can-
cers through various genetic alterations including point mutations
(missense and nonsense mutations), large chromosomal dele-
tions (homozygous/heterozygous deletion, frameshift, inframe
deletion, and truncation), and epigenetic mechanisms as hyper-
methylation of the PTEN promoter region. In addition, PTEN
could be inactivated by other non-structural alterations affecting
transcript stability, protein stability, and differential subcellular
compartmentalization (4, 5, 8).
Despite its serine, threonine and tyrosine phosphatase activ-
ity, the lipid phosphatase function of PTEN has been shown to
be the major driving force in tumor suppression. In fact the
G129E mutation, observed in cancer specimens and abrogating the
lipid phosphatase activity but maintaining its protein phosphatase
activity, leads to PTEN tumor suppressor function inactivation
in vitro (11–13).
Loss of heterozygosity at 10q23 occurs frequently in many spo-
radic tumors at advanced stage; for example, approximately 70%
glioblastoma and 60% advanced prostate cancer are characterized
by loss of that region. Somatic mutation in the second allele of
PTEN, which results in biallelic inactivation, occurs in 25–40% of
glioblastomas.
Somatic mutations of PTEN have been identified as the main
mechanism of inactivation in many tumor types,particularly those
of the endometrium, brain, skin, and prostate. The tumor suppres-
sor function of PTEN is usually abrogated following mutations
occurring in its phosphatase domain (encoded by exon 5): typi-
cally, the C124S mutation (that abrogates both lipidic and protein
phosphatase activity) and the G129E mutation (that abrogates
only lipid phosphatase activity) (4, 14). Although the N-terminal
phosphatase domain is principally responsible for PTEN physio-
logical activity, approximately 40% of PTEN tumorigenic muta-
tions may occur in the C-terminal C2 domain (corresponding
to exons 6, 7, and 8) and in the tail sequence (corresponding
to exon 9), encoding for tyrosine kinase phosphorylation sites
important for maintaining PTEN function and protein stability
(3, 4, 8, 15). In endometrial carcinoma, glioblastoma, and lym-
phoma, cancer-specific mutations have been found also in the
PIP2-binding region, thus highlighting the importance of this
motif for the functionality of PTEN protein (16, 17). In addition to
missense mutations, a number of nonsense and frameshift muta-
tions have been described leading to truncated PTEN proteins
lacking the C-terminal tail and the PDZ-interaction motif, impor-
tant domains for PTEN protein stability and recruitment to the
membrane, without which PTEN is biochemically inactive (5, 8).
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However, in sporadic tumors, loss of heterozygosity of PTEN
occurs at a much higher frequency than biallelic inactivation. It
remains unclear whether haploinsufficiency of PTEN provides a
selective growth advantage in tumors lacking a second hit in the
remaining PTEN allele. Evidence for a role of PTEN haploinsuffi-
ciency was demonstrated in a mouse model of prostate cancer in
which the dosage of PTEN was inversely correlated to the severity
of tumor phenotype (18).
Finally, PTEN can be altered also in inherited syndromes. That
is the case of the Cowden disease whose patients tend to develop
breast, thyroid, and skin tumors. In these types of tumor PTEN
exerts its role in the initiation and in the progression of cancer (3,
12, 19).
PTEN IN COLORECTAL CANCER
In CRC PTEN is altered through a mixed genetic/epigenetic mech-
anism (typically: mutations and promoter hypermethylation or
10q23 LOH and promoter hypermethylation), which leads to the
biallelic inactivation of the protein in 20–30% of cases.
PTEN expression and mutational rate was reported to be lower
in left-sided (distal) CRC in comparison to right-sided (proximal)
cancers (20–22). This finding may be related to different genetic
mechanisms underlying the tumorigenesis of proximal and distal
sporadic CRCs. Cancers arising in right colon are usually charac-
terized by microsatellite instability (MSI), whereas those arising in
the distal colon and in the rectum are very often characterized by
chromosomal instability (CIN). Therefore, it can be argued that
PTEN alterations may be linked to MSI and to the mechanisms
leading to MSI (including high frequency of promoter hyperme-
thylation, the main mechanism of mismatch repair genes silencing,
whose absence of function is directly responsible of MSI). Con-
sistent with this hypothesis, Day and colleagues found that PTEN
mutations, identified in about 6% out of 744 stage I-IV CRC, were
associated with mucinous histology, MSI, CpG island methylator
phenotype, and BRAF mutations (22). Furthemore, other reports
demonstrated a direct association between PTEN mutations and
MSI, suggesting that the PTEN gene is a target of genomic insta-
bility in MSI colorectal tumorigenesis (23–25). In particular, Zhou
and colleagues found that among 11 HNPCC CRC, 32 MSI spo-
radic cancer, and 39 microsatellite stable tumors, PTEN somatic
mutations were found in 18, 13, and 0% of cases respectively, and
PTEN loss of expression (evaluated by IHC) in 31, 41, and 17%,
respectively. The majority of somatic mutations occur in the two
6(A) coding mononucleotide tracts, suggesting an etiological role
of the deficient mismatch repair system (25). Moreover, it was
also reported that PTEN promoter hypermethylation is a frequent
event in sporadic CRC with MSI and may represent an impor-
tant epigenetic mechanism of PTEN inactivation in this setting
(26).
Overall, although another study did not confirm this associa-
tion (because gene mutations and LOH were found in about 20
and 17% of sporadic CRC respectively, all but one of which were
microsatellite stable) (27), we can assume that PTEN alterations
and MSI are correlated.
In addition to PTEN level, the PI3K pathway can be altered
following mutations in genes encoding for PI3K proteins, typi-
cally in PIK3CA gene. Therefore, it has been proposed that PTEN
alterations and PIK3CA mutations may be mutually exclusive.
However, this concept has not been deeply demonstrated as few
studies investigating this topic showed conflicting results. There is
in fact a clear evidence that mutations in multiple components
of the PI3K pathway are not necessarily redundant. Although
activating mutations in PI3K and loss of PTEN function both
enhance PI3K signaling, these alterations seem not to cover equiv-
alent functions. For example, in endometrial cancer, mutations
in PTEN and PIK3CA both occur frequently and often concomi-
tantly within the same tumor, indicating a potential additive or
synergistic effect (28–30).
As for the other genetic alterations mainly occurring in CRC, it
has been demonstrated that loss of PTEN expression measured by
IHC co-occurs with KRAS and BRAF mutations and with EGFR
polysomy (31), whereas PTEN and TP53 mutations seem to be
mutually exclusive (27).
PROGNOSTIC ROLE OF PTEN
The role of PTEN as a prognostic factor in CRC has been addressed
by relatively few works.
Although accumulating evidence has strongly suggested that
PTEN is a crucial factor in various central processes of cancer
development, and although in several tumor types (e.g., non-
small-cell lung cancer, prostate and breast cancer) PTEN protein
status has been correlated with poor prognosis, the association
between PTEN expression and clinical parameters in CRC is still
controversial. The studies reporting the clinical impact of PTEN
alterations on patient outcome in CRC are here summarized. Sev-
eral of these studies suggest an association between loss of PTEN
protein expression with advanced disease, liver metastasis, and
poor patient survival, whereas other works do not find such an
association (Tables 1 and 2).
One of the first paper reporting an association between PTEN
alteration and tumor aggressiveness was published in 2001 and
examinedPTEN somatic mutations in a series of 36 sporadic CRC.
The authors found that PTEN gene mutations were detected only
in patients with locally advanced or metastatic CRC (32).
The majority of the next studies have been performed by ana-
lyzing PTEN protein expression by IHC assay, the most effective
way to assess the loss of PTEN function by any mechanism (LOH,
somatic mutation, or promoter epigenetic silencing). In fact, it
has been reported that all tumors with PTEN gene alterations
(mutation and/or deletion) showed a reduction or absence of
PTEN expression evaluated by IHC, and this finding was corre-
lated with advanced stage of disease (33). This association was
confirmed by Sawai and colleagues, who demonstrated that PTEN
loss was significantly correlated with local recurrence, advanced
TNM stage (p< 0.01), lymph node metastasis (p< 0.05) and
with lower 5-year survival rate (p= 0.012), indicating a link
between PTEN deregulation and CRC aggressive phenotype (34).
A positive association of PTEN expression with histological grade
and distant metastasis was also demonstrated by Lin and col-
leagues (35). Similarly, Li and co-workers, by examining nuclear
PTEN protein expression on tissue microarray in 327 CRC, found
that low level of PTEN protein expression was positively cor-
related with tumor size, depth of invasion, lymphatic invasion,
lymph node metastasis, and higher tumor staging (p< 0.05).
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Table 1 | List of papers finding a positive correlation between PTEN loss and prognosis.
Author No. Type of tissue Method % PTEN alteration
Dicuonzo et al. (32) 36 Frozen CRC Sequencing 17% mutations
Nassif et al. (33) 41 Frozen normal tissue and CRC Sequencing, LOH, IHC 19% mutations
17% LOH
70% reduction or loss of expression
(IHC) (cytoplasm and nuclear staining)
Sawai et al. (34) 69 with liver metastasis;
70 without liver metastasis
FFPE CRC and liver metastasis IHC 75.4% weak expression (cytoplasm
and nuclear staining)
Lin et al. (35) 139 FFPE TMA CRC IHC 7% weak or loss expression
(cytoplasm staining)
Li et al. (36) 327 FFPE TMA CRC Sequencing, IHC 29% weak or loss of expression (PTEN
immunoreactivity localized in the
nucleus)
Jang et al. (37) 482 FFPE TMA CRC IHC 50% loss of expression
Jin et al. (38) 68 FFPE CRC IHC 67.6% loss of expression (cytoplasm
and nuclear staining)
Atreya et al. (39) 56 FFPE mCRC IHC 12.3% loss of expression (cytoplasm
and nuclear staining)
Bohn et al. (40) 307 FFPE TMA CRC FISH 8.8% gene loss
No.: number of patients; CRC: colorectal cancer; FFPE: formalin-fixed paraffin embedded; FISH: fluorescent in situ hybridization; IHC: immunohistochemistry; LOH:
loss of heterozygosity; mCRC: metastatic colorectal cancer; TMA: tissue microarray.
Table 2 | List of papers finding no correlation between PTEN loss and prognosis.
Author No. Type of tissue Method % PTEN alteration
Colakoglu et al. (21) 76 FFPE CRC IHC 5% loss of expression; 67% weakly moderate
positive expression (cytoplasm staining)
Eklöf et al. (41) 197 and 414* FFPE CRC IHC 12.5 and 14% loss of expression (cytoplasm staining)
Price et al. (42) 302 FFPE advanced CRC Taqman copy number assay 38.7% loss
Day et al. (22) 1093 FFPE stage I-IV CRC Sequencing 5.8% mutations
*Separate cohort; No.: number of patients; CRC: colorectal cancer; FFPE: formalin-fixed paraffin embedded; IHC: immunohistochemistry.
In addition, univariate and multivariate analysis indicated that
patients characterized by PTEN loss of protein expression had a
shorter survival than patients with a normal expression of PTEN
(36).
Another study performed on 482 CRC revealed that PTEN
protein expression (evaluated again on a tissue microarray) was
associated with poor overall survival (OS) and disease-free survival
(p= 0.03 and p= 0.046, respectively), although in multivariate
analysis, a significant difference was observed only in patients with
stage II of disease (37).
Jin and colleagues by evaluating the prognostic value of PTEN,
STAT3, and VEGF-C protein expression by IHC in 68 cases of
CRC, showed that PTEN expression was correlated with patho-
logical grade, but not with tumor size, lymph node metastasis, or
clinical stage. Moreover the 3- and 5-years survival rates of patients
normally expressing PTEN were significantly higher than those of
patients with a PTEN-negative tumor (38).
In a very recent study conducted on 56 patients affected by a
metastatic disease, PTEN protein expression was analyzed by an
optimized PTEN IHC assay recently developed and it was found
that the median OS of patients whose tumors did not express
PTEN was 9 months, compared to 49 months for patients with a
normal expression of PTEN [HR= 6.25, 95% confidence intervals
(CI), p= 0.0023]. The association of absence of PTEN expression
with increased risk of death remained significant in multivariate
analysis (Hazard Ratio, HR= 6.31, 95% CI, p= 0.0023) (39).
Finally, the positive correlation between worse prognosis and
PTEN alteration was also found after the analysis of genetic lesions.
Through the evaluation of PTEN deletion and gene rearrange-
ments by FISH on 307 CRC, the authors confirmed an association
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between PTEN alteration with reduced patient survival in uni-
variate and multivariate analyses in rectal cancer (p= 0.012, HR
2.675; 95% CI) but not in colon cancer (40).
On the contrary with respect to the results obtained by the
studies reported above, Colakoglu and colleagues, by investigating
76 CRC patients, found no correlation between PTEN immuno-
histochemical status and patient survival, tumor grade, TNM
stage, lymphatic invasion, and liver metastasis (21), although they
found a significant association between PTEN loss and local recur-
rence. Another study investigating the prognostic role of KRAS,
BRAF, PIK3CA mutations, and PTEN expression in two sepa-
rate CRC cohorts of 197 and 414 patients respectively, observed
absence of correlation between PTEN status and prognosis by
analyzing each molecular marker separately (41). The prognos-
tic value of PTEN was also explored through the evaluation of
PTEN gene copy number alteration (CNA) assessed by a Taqman
assay by Price and colleagues in a cohort of 302 patients with
advanced CRC enrolled in the AGITG MAX trial, a randomized
Phase III trial of capecitabine± bevacizumab or mitomycin C.
The authors did not find any correlation between PTEN status
and progression free survival (PFS) or OS in multivariate analysis
(42). The absence of association with prognosis in stage II and
III CRC was also supported by the work of Day and colleagues
who analyzed PTEN mutations in a large cohort of sporadic
CRC (22).
In conclusion, at the moment there are no clinical data clearly
supporting the notion of PTEN alteration as a prognostic factor
in CRC.
PREDICTIVE ROLE OF PTEN IN EGFR-TARGETED THERAPIES
RESPONSE
In addition to the evaluation of the prognostic role of PTEN,
several studies have investigated its predictive role in the field
of targeted therapies. Since in breast cancer patients it has been
demonstrated that PTEN loss of expression confers resistance
to trastuzumab (a monoclonal antibody, MoAb, against Her-2,
a tyrosine kinase receptor belonging to the Her family, as EGFR)
(43), recent reports have investigated whether PTEN alterations
may affect responsiveness of mCRC patients to anti-EGFR MoAbs
cetuximab and panitumumab (Table 3). These studies have pri-
marily used IHC to assess expression at protein level, and some
have shown a correlation between PTEN expression and clinical
response. A preliminary work on a retrospective series of patients
reported that loss of PTEN expression, observed in 40% of pri-
mary tumor in mCRC patients, was significantly associated with
non-responsiveness to cetuximab (44). The authors found that no
patients with PTEN loss of expression in tumor tissue responded
to a combination of irinotecan and cetuximab, whereas 10 out
of 16 (63%) patients with intact PTEN expression experienced
a partial response to these therapies. In vitro studies have con-
firmed this evidence by showing that PIK3CA mutations or PTEN
loss may predict the efficacy of cetuximab administration in colon
cancer cell lines (45). The role of PTEN in predicting resistance
to anti-EGFR MoAbs was confirmed by Sartore-Bianchi and col-
leagues, who found that loss of PTEN protein was associated with
lack of response to cetuximab and panitumumab (p= 0.001) in a
cohort of 81 tumor specimens. Loss of PTEN expression was also
Table 3 | List of papers investigating the predictive role of PTEN in CRC treated with EGFR-targeted therapies cetuximab or panitumumab.
Author No. Type of tissue Method % PTEN alteration and clinical response
Frattini et al. (44) 27 FFPE mCRC IHC 100% PTEN-negative patients were NR (p<0.001)
Sartore-Bianchi et al. (46) 81 FFPE mCRC IHC 97% PTEN-negative patients were NR (p=0.001)
Perrone et al. (47) 32 FFPE mCRC Sequencing, FISH All patients with a decreased PTEN gene copy number or
with PTEN mutation were NR
Razis et al. (48) 72 FFPE mCRC IHC and FISH PTEN gene deletion detected only by FISH associated
with no response
Loupakis et al. (49) 102 FFPE mCRC (primary
and metastatic lesion)
IHC 95% PTEN-negative patients were NR. Association with
clinical response found only in the metastatic lesion
Negri et al. (50) 50 FFPE mCRC (primary
and metastatic lesion)
Immunofluorescence 100% PTEN-negative patients were NR (p<0.05).
Association with clinical response found only in the
metastatic lesion
Tol et al. (51) 559 FFPE mCRC IHC Loss of PTEN expression observed in 42% but not
associated with response
Ulivi et al. (52) 67 FFPE mCRC IHC Loss of PTEN expression observed in 60% but not
associated with response
Laurent-Puig et al. (53) 162 FFPE mCRC IHC Loss of PTEN expression observed in 19% but not
associated with response
No: number of patients; CRC: colorectal cancer; FFPE: formalin-fixed paraffin embedded; FISH: fluorescent in situ hybridization; IHC: immunohistochemistry; mCRC:
metastatic colorectal cancer; NR: non-responder to anti-EGFR therapies.
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associated with shorter PFS and worse OS (46). Supporting these
data, another study showed that inactivation of PTEN protein by
gene mutation or deletion (detected by FISH) was responsible of
cetuximab resistance (47). Razis and colleagues, did not find any
association between PTEN protein expression as evaluated by IHC
with clinical outcomes, although the lack of PTEN gene amplifica-
tion evaluated by FISH was associated with a better response rate
and longer time to progression (48).
A substantial but not complete confirmation of these data has
been reported by Loupakis and colleagues which demonstrated
that loss of PTEN expression was not associated with resistance
to cetuximab plus irinotecan in the primary tumor (n= 96), but
was associated with lack of response in the metastatic lesion (the
analysis was performed in 59 cases). In the PTEN-positive group,
12 out of 33 (36%) patients benefited from the therapy whereas
only 1 patient out of 22 (5%) cases with a PTEN-negative pro-
file responded to EGFR-targeted drugs (p= 0.007). Moreover,
patients with PTEN-positive metastases and KRAS wild-type gene
sequence had longer PFS compared with other patients (49).
According to these data, Negri and colleagues evaluated PTEN
expression by immunofluorescence both in primary and metasta-
tic sites in CRC patients treated with cetuximab and they found
that the loss of PTEN expression in metastatic sites was negatively
associated with response (50).
On the contrary with respect to the previous works, other
studies failed to demonstrate a correlation between loss of PTEN
expression and response to anti-EGFR MoAbs. In a large cohort
of 559 mCRC patients treated with chemotherapy and beva-
cizumab with or without cetuximab (phase III CAIRO2 study),
the authors did not find any correlation between PTEN loss
evaluated by IHC and response to treatment with cetuximab, nei-
ther individually nor in combination with other markers (51).
This result was confirmed by Ulivi et al. by the analysis of 67
mCRC patients receiving cetuximab (52). Finally, the investiga-
tion of 162 samples by Laurent-Puig and colleagues reported
the PTEN null expression rate of 19.9% with an association of
poorer OS in the KRAS wild-type population (p= 0.013) but
not with tumor response or PFS, thus suggesting the PTEN
loss of expression as a prognostic rather than a predictive
role (53).
CONCLUSION
According to the reported results, the role played by PTEN as a
prognostic or predictive marker in CRC is still a matter of debate.
Discordant results have been reported and this fact could be attrib-
utable to several issues: (1) the size of the analyzed cohort, (2)
patients inclusion criteria, (3) the methods of assessing PTEN
alteration. For the latter point, it should be noted that the major-
ity of studies have evaluated PTEN alteration by IHC, the easier
and cheaper method to be used. However, these studies showed
highly discordant results, with PTEN loss ranging from 5% up
to 66% (40). Reasons for this variability might include inher-
ent issues with IHC. Interpreting PTEN data can be challenging,
because immunohistochemistry can produce variable results. The
lack of standardized methods and the variability of tissue han-
dling may bias the PTEN expression analysis by IHC. In addi-
tion, IHC is afflicted by intra and inter-observer variability due
to the semi-quantitative character of such an analysis. A stan-
dard, universally accepted PTEN testing and scoring system for
PTEN IHC evaluation, has yet to be established. Assessment of
PTEN expression is further complicated by potential discordance
between the expression of PTEN in the primary and in the metasta-
tic tissue. Concordance rates vary from 47 to 98% between primary
and metastatic lesions (39, 49, 54–56). These differences may
impair the prediction of anti-EGFR therapies outcome. Loupakis
and colleagues reported in fact that PTEN loss was predictive
of cetuximab resistance only by evaluating the metastatic lesion
(49). Sangale and co-workers however, has recently developed an
optimized PTEN IHC assay developed through a rigorous testing
of antibody specificity and selectivity using samples with known
molecular alterations in PTEN, paired with reproducible method
of interpretation. The Authors found a 98% of concordance of
PTEN expression between primary and metastatic tumors (57).
Another issue that has recently emerged is the intracellular local-
ization of PTEN protein. Some researchers demonstrated that
PTEN is localized both in the cytoplasm and into the nucleus
and shuttles between these two compartments can be influenced
by a variety of mechanisms. Accumulating genetic, pathologic and
biochemical evidence suggests that the localization of PTEN either
in the nucleus or cytoplasm may affect the proliferation of tumor
cells (58–60). Another point that could affect the establishment
of the prognostic and predictive value of PTEN is haploinsuffi-
ciency, determined when only one allele is altered, as it remains
unclear whether this condition could provide a selective growth
advantage in tumors lacking a second hit in the remaining PTEN
allele.
To clarify the problems concerning PTEN evaluation, it would
be necessary a comparison of the results obtained by analyzing
the several PTEN alterations through different methodologies
(FISH, promoter methylation, LOH, and immunohistochemistry
performed with different antibodies) both on cancer cell lines with
a well known PTEN status and on a large series of patients in order
to better establish IHC evaluation criteria. An international inter-
laboratory reproducibility ring study [as that performed for EGFR
FISH analysis in metastatic colorectal cancer (CRC) patients] (61)
is missing and has to be performed in order to ascertain the dif-
ficulties and the discrepancies in PTEN evaluations in different
laboratories.
In conclusion,much work,especially in large and homogeneous
cohorts of cases from different laboratories, has to be done before
the establishment of PTEN as prognostic or predictive marker in
CRC. On the contrary, in other tumor types (such as breast cancer),
this role is clearer.
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